Michael Laffan

19.5k total citations · 3 hit papers
235 papers, 8.7k citations indexed

About

Michael Laffan is a scholar working on Hematology, Internal Medicine and Genetics. According to data from OpenAlex, Michael Laffan has authored 235 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Hematology, 46 papers in Internal Medicine and 37 papers in Genetics. Recurrent topics in Michael Laffan's work include Platelet Disorders and Treatments (83 papers), Hemophilia Treatment and Research (51 papers) and Blood Coagulation and Thrombosis Mechanisms (47 papers). Michael Laffan is often cited by papers focused on Platelet Disorders and Treatments (83 papers), Hemophilia Treatment and Research (51 papers) and Blood Coagulation and Thrombosis Mechanisms (47 papers). Michael Laffan collaborates with scholars based in United Kingdom, United States and Germany. Michael Laffan's co-authors include James S. O’Donnell, Richard A. Manning, Thomas A. J. McKinnon, Will Lester, John Pasi, Robert C. Tait, David Keeling, David J. Perry, Deepa J. Arachchillage and Andrew Mumford and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Michael Laffan

221 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AAV5–Factor VIII Gene Transfer in Severe Hemophilia A

2017 515 citations Savita Rangarajan, Will Lester et al. profile →
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

2020 327 citations Savita Rangarajan, Will Lester et al. profile →
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

2021 181 citations Michael Laffan et al. profile →

Peers

Countries citing papers authored by Michael Laffan

Since Specialization

Citations

This map shows the geographic impact of Michael Laffan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Laffan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Laffan more than expected).

Fields of papers citing papers by Michael Laffan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Laffan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Laffan. The network helps show where Michael Laffan may publish in the future.

Co-authorship network of co-authors of Michael Laffan

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Laffan. A scholar is included among the top collaborators of Michael Laffan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Laffan. Michael Laffan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom 2025 ·European Journal Of Haematology ·Michael Laffan, (unknown), Cheryl Jones, (unknown), (unknown), (unknown), (unknown)	1
2	Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies 2024 ·BMC Health Services Research ·(unknown), Amit Chhabra, Tom Burke, Jack Brownrigg, (unknown), (unknown), Jamie O’Hara, (unknown), Michael Laffan	0
3	Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 versus Vaccine-induced Immune Thrombocytopenia and Thrombosis in the United Kingdom 2024 ·Seminars in Thrombosis and Hemostasis ·Deepa J. Arachchillage, (unknown), Μichael Μakris, Michael Laffan, (unknown)	1
4	Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis 2024 ·Haematologica ·Nicola Curry, (unknown), Gael B. Morrow, Robin P. Choudhury, Michael Laffan	0
5	Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment 2024 ·Haemophilia ·Emily Symington, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, (unknown), Tara M. Robinson, (unknown), Chris B. Russell, Christian Vettermann, Suresh Agarwal, Mingjin Li, Wing Yen Wong, Michael Laffan	17
6	Expert United Kingdom consensus on the preservation of joint health in people with moderate and severe haemophilia A: A modified Delphi panel 2024 ·Haemophilia ·Michael Laffan, Paul McLaughlin, Jayashree Motwani, Jayanthi Alamelu, Steve Austin, (unknown), Gerard Dolan, (unknown), Richard Gooding, John D. Grainger, Catherine Harrison, (unknown), Anne M. Kelly, (unknown), (unknown), David Stephensen, Kate Talks, (unknown), (unknown)	0
7	Traumatic coagulopathy in the older patient: analysis of coagulation profiles from the Activation of Coagulation and Inflammation in Trauma-2 (ACIT-2) observational, multicenter study 2023 ·Journal of Thrombosis and Haemostasis ·Nicola Curry, Ross Davenport, Henna Wong, Christine Gaarder, Pär I. Johansson, Nicole P. Juffermans, Marc Maegele, Jakob Stensballe, Karim Brohi, Michael Laffan, Simon Stanworth	7
8	Practical treatment guidance for cancer-associated thrombosis – Managing the challenging patient: A consensus statement 2022 ·Critical Reviews in Oncology/Hematology ·Kathryn Musgrave, (unknown), Michael Laffan, James S. O’Donnell, Jecko Thachil, Anthony Maraveyas	7
9	The Cost of Von Willebrand Disease in Europe: The CVESS Study 2022 ·Clinical and Applied Thrombosis/Hemostasis ·(unknown), (unknown), Michael Laffan, Jenny Goudemand, (unknown), Alan Finnegan	3
10	Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel 2022 ·BMC Medical Genomics ·(unknown), Yock Ping Chow, (unknown), Kian Meng Chang, (unknown), (unknown), (unknown), Abhi Veerakumarasivam, Michael Laffan, CL Wong	2
11	Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study 2021 ·Journal of the American Heart Association ·Shuai Yuan, Stephen Burgess, Michael Laffan, Amy M. Mason, Martin Dichgans, Dipender Gill, Susanna C. Larsson	21
12	Platelet function in patients with chronic myeloid leukemia treated with asciminib 2020 ·Leukemia & lymphoma ·(unknown), Michael Laffan, Simone Claudiani, Andrew J. Innes, Jane F. Apperley, Dragana Milojković	1
13	A Mendelian randomization of γ′ and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke 2020 ·Blood ·(unknown), Dipender Gill, Nathan Pankratz, Michael Laffan, Alisa S. Wolberg, Moniek P.M. de Maat, Symen Ligthart, Weihong Tang, Cavin Ward‐Caviness, Myriam Fornage, Stéphanie Debette, Martin Dichgans, Barbara McKnight, Eric Boerwinkle, (unknown), Nicholas L. Smith, Alanna C. Morrison, Abbas Dehghan, Paul S. de Vries	32
14	Respiratory patient experience of measures to reduce risk of COVID-19: findings from a descriptive cross-sectional UK wide survey 2020 ·BMJ Open ·Keir Philip, Andrew Cumella, (unknown), Michael Laffan, Nicholas S Hopkinson	43
15	The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing 2019 ·Blood ·Jun Ishihara, Ako Ishihara, Richard Starke, Claire Peghaire, (unknown), Thomas A. J. McKinnon, Yoji Tabata, Koichi Sasaki, Michael White, Kazuto Fukunaga, Michael Laffan, Matthias P. Lütolf, Anna M. Randi, Jeffrey A. Hubbell	88
16	Patterns of breathlessness and associated consulting behaviour: results of an online survey 2019 ·Thorax ·Amany F. Elbehairy, Jennifer K Quint, (unknown), Michael Laffan, Michael I. Polkey, Nicholas S Hopkinson	20
17	Associations of genetically determined iron status across the phenome: A mendelian randomization study 2019 ·PLoS Medicine ·Dipender Gill, Beben Benyamin, Luke Moore, Grace Monori, Ang Zhou, Fotios Koskeridis, Εvangelos Εvangelou, Michael Laffan, Ann P. Walker, Konstantinos K. Tsilidis, Abbas Dehghan, Paul Elliott, Elina Hyppönen, Ioanna Tzoulaki	41
18	Genetically Determined FXI (Factor XI) Levels and Risk of Stroke 2018 ·Stroke ·Dipender Gill, Marios K. Georgakis, Michael Laffan, Maria Sabater‐Lleal, Rainer Malik, Ioanna Tzoulaki, Roland Veltkamp, Abbas Dehghan	38
19	Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry 2008 ·British Journal of Haematology ·Vickie McDonald, Michael Laffan, Sylvia Benjamin, David Bevan, Samuel J. Machin, Marie Scully	34
20	Bleeding symptoms and coagulation test abnormalities in 308 patients with AL amyloidosis 1999 ·UCL Discovery (University College London) ·(unknown), James S. O’Donnell, (unknown), (unknown), Philip N. Hawkins, Michael Laffan	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact